


## AN11251

Cat. No.:	HY-111543
CAS No.:	2130750-59-1
Molecular Formula:	C <sub>29</sub> H <sub>38</sub> BF <sub>7</sub> O <sub>7</sub>
Molecular Weight:	528.42
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	AN11251 is a potent and oral active anti- <i>Wolbachia</i> agent with potential for treatment of onchocerciasis and lymphatic filariasis, with EC <sub>50</sub> values of 1.5 nM in LDW1 cell lines and 15 nM in C6/36 cell lines <sup>[1]</sup> .								
<b>In Vivo</b>	<p>AN11251 (25 mg/kg, PO, BID for 7 or 14 days) reduces the Wolbachia load in the B. malayi larvae by 75.4% and 98.8% in the 7- and 14-day treatment groups, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CB.17 SCID mice inoculated with 50 L3-stage B. malayi larvae<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Orally, BID for 7 or 14 days.</td> </tr> <tr> <td>Result:</td> <td>Reduced the Wolbachia load in the B. malayi larvae by 75.4% and 98.8% in the 7- and 14-day treatment groups, respectively.</td> </tr> </table>	Animal Model:	CB.17 SCID mice inoculated with 50 L3-stage B. malayi larvae <sup>[1]</sup> .	Dosage:	25 mg/kg.	Administration:	Orally, BID for 7 or 14 days.	Result:	Reduced the Wolbachia load in the B. malayi larvae by 75.4% and 98.8% in the 7- and 14-day treatment groups, respectively.
Animal Model:	CB.17 SCID mice inoculated with 50 L3-stage B. malayi larvae <sup>[1]</sup> .								
Dosage:	25 mg/kg.								
Administration:	Orally, BID for 7 or 14 days.								
Result:	Reduced the Wolbachia load in the B. malayi larvae by 75.4% and 98.8% in the 7- and 14-day treatment groups, respectively.								

### REFERENCES

[1]. Jacobs RT, et al. Boron-Pleuromutilins as Anti-*Wolbachia* Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. *J Med Chem.* 2019 Mar 14;62(5):2521-2540.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA